The Analyst Verdict: Clene In The Eyes Of 5 Experts

Ratings for Clene CLNN were provided by 5 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.

The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.

Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $6.6, along with a high estimate of $7.00 and a low estimate of $5.00. Observing a downward trend, the current average is 5.71% lower than the prior average price target of $7.00.

Breaking Down Analyst Ratings: A Detailed Examination

A comprehensive examination of how financial experts perceive Clene is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.

Key Insights:

• Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Clene. This information offers a snapshot of how analysts perceive the current state of the company.
• Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Clene compared to the broader market.
• Price Targets: Delving into movements, analysts provide estimates for the future value of Clene's stock. This analysis reveals shifts in analysts' expectations over time.

Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Clene's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.

Stay up to date on Clene analyst ratings.

If you are interested in following small-cap stock news and performance you can start by tracking it here.

Unveiling the Story Behind Clene

Clene Inc is a clinical-stage pharmaceutical company pioneering the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. It is focused on the development of therapeutics for neurodegenerative diseases. It developed an electro-crystal-chemistry drug development platform that enables the production of concentrated, stable, clean-surfaced nanocrystal suspensions. It operates in one segment the development and commercialization of dietary supplements (Supplements).

Breaking Down Clene's Financial Performance

Market Capitalization: Surpassing industry standards, the company's market capitalization asserts its dominance in terms of size, suggesting a robust market position.

Revenue Growth: Clene's revenue growth over a period of 3 months has faced challenges. As of 31 December, 2023, the company experienced a revenue decline of approximately -27.35%. This indicates a decrease in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.

Net Margin: Clene's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of -5984.12%, the company may face hurdles in effective cost management.

Return on Equity (ROE): Clene's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -58.47% ROE, the company effectively utilizes shareholder equity capital.

Return on Assets (ROA): Clene's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of -18.04%, the company may face hurdles in achieving optimal financial performance.

Debt Management: Clene's debt-to-equity ratio is notably higher than the industry average. With a ratio of 2.4, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.

The Core of Analyst Ratings: What Every Investor Should Know

Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.

Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.

This article was generated by Benzinga's automated content engine and reviewed by an editor.